BidaskClub upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a buy rating in a report published on Monday, January 15th.
Several other analysts have also issued reports on the stock. Robert W. Baird reissued an outperform rating and issued a $16.00 price target on shares of Amicus Therapeutics in a research report on Monday, September 25th. Zacks Investment Research lowered shares of Amicus Therapeutics from a hold rating to a sell rating in a report on Tuesday, December 19th. Bank of America upped their target price on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the stock a buy rating in a report on Wednesday, October 4th. Goldman Sachs Group reaffirmed a neutral rating and set a $17.00 target price on shares of Amicus Therapeutics in a report on Friday, October 6th. Finally, JPMorgan Chase & Co. reaffirmed an overweight rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $18.31.
Amicus Therapeutics (FOLD) opened at $15.90 on Monday. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. The firm has a market cap of $2,640.00, a PE ratio of -8.69 and a beta of 1.72. Amicus Therapeutics has a 52 week low of $5.07 and a 52 week high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The company had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $9.02 million. During the same quarter in the previous year, the firm earned ($0.33) earnings per share. The firm’s revenue was up 419.0% compared to the same quarter last year. equities research analysts anticipate that Amicus Therapeutics will post -1.52 EPS for the current year.
In other Amicus Therapeutics news, CFO William D. Baird III sold 10,000 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total transaction of $147,200.00. Following the completion of the sale, the chief financial officer now owns 105,121 shares of the company’s stock, valued at approximately $1,547,381.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jay Barth sold 5,000 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $13.59, for a total transaction of $67,950.00. Following the completion of the transaction, the insider now owns 69,184 shares of the company’s stock, valued at $940,210.56. The disclosure for this sale can be found here. Insiders sold a total of 197,890 shares of company stock valued at $2,767,181 in the last ninety days. 3.40% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio bought a new position in Amicus Therapeutics in the 3rd quarter worth $102,000. Birchview Capital LP bought a new position in Amicus Therapeutics in the 3rd quarter worth $151,000. Sage Capital Advisors llc bought a new position in Amicus Therapeutics in the 3rd quarter worth $154,000. Engineers Gate Manager LP bought a new position in Amicus Therapeutics in the 3rd quarter worth $155,000. Finally, Tudor Investment Corp ET AL bought a new position in Amicus Therapeutics in the 2nd quarter worth $124,000.
TRADEMARK VIOLATION WARNING: This story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/22/amicus-therapeutics-fold-upgraded-to-buy-by-bidaskclub-3.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.